Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73830 | 0.82 | LMNA (0.38) | ADAMTS5LMNAADAM17PDE7AALDH1A1 | |
| SCHEMBL2963931 | 0.82 | LMNA (0.38) | ADAMTS5LMNAADAM17PDE7AALDH1A1 | |
| SCHEMBL27758977 | 0.78 | LMNA (0.40) | ADAMTS5LMNAADAM17PDE7AALDH1A1 | |
| SCHEMBL6699900 | 0.77 | PDE7A (0.44) | ADAMTS5LMNAADAM17PDE7AALDH1A1 | |
| SCHEMBL1404437 | 0.77 | LMNA (0.50) | ADAMTS5LMNAADAM17PDE7AALDH1A1 | |
| SCHEMBL2967748 | 0.75 | SMN1; SMN2 (0.43) | ADAMTS5ADAM17MMP13ALDH1A1 | |
| SCHEMBL6692266 | 0.74 | LMNA (0.40) | ADAMTS5LMNAMMP13PDE7AALDH1A1 | |
| SCHEMBL6662375 | 0.74 | LMNA (0.43) | ADAMTS5LMNAADAM17MMP14PDE7A | |
| SCHEMBL11167483 | 0.73 | MMP2 (0.42) | ADAMTS5LMNAMMP13 | |
| SCHEMBL11534742 | 0.71 | MMP2 (0.45) | ADAMTS5LMNAMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772403-B2 | Process to prepare sulfonyl chloride derivatives | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20090054659-A1 | Process to Prepare Sulfonyl Chloride Derivatives | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1999115-A1 | PROCESS TO PREPARE SULFONYL CHLORIDE DERIVATIVES | AstraZeneca AB (SE) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007106021-A1 | PROCESS TO PREPARE SULFONYL CHLORIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
| US-20060019994-A1 | I-sulphonlyl piperidine derivatives | ASTRAZENECA AB (SE) | 2006-01-26 | — | — | US | disclosed |
| EP-1539706-A1 | 1-SULPHONYL PIPERIDINE DERIVATIVES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024698-A1 | 1-SULPHONYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019994-A1 | I-sulphonlyl piperidine derivatives | MMP1, TPSAB1, CASP1 | ADAMTS5 214/4885LMNA 4174/4885ADAM17 105/4885 |
| US-20090054659-A1 | Process to Prepare Sulfonyl Chloride Derivatives | SLC5A1, GCG, IAPP | ADAMTS5 4661/4885LMNA 1199/4885ADAM17 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.